Danshensu for Myocardial Ischemic Injury: Preclinical Evidence and Novel Methodology of Quality Assessment Tool

• Egile Nagusiak: Xiao-yi Bao (Egilea), Qun Zheng (Egilea), Qiang Tong (Egilea), Peng-chong Zhu (Egilea), Zhuang Zhuang (Egilea), Guo-qing Zheng (Egilea), Yan Wang (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2018-12-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: Danshensu (DSS) possesses unique bioactivity on the cardiovascular system. However, there is a lack of systematical summary of DSS for acute myocardial ischemia injury and no quality assessment tool for the systematical review of cell experiments. Here, we aimed to assess the preclinical...